David is a Partner at Maven Capital Partners where he is a member of Maven’s Investment Committee and is responsible for sourcing and executing growth capital and private equity investments in Scotland as well as technology and life science investments across the UK. His current investments include BioAscent, QikServe, Guru Systems and Carcinotech.

David started his career as a scientist with GSK. After completing his PhD, he moved to international consultancy firm Wood Mackenzie (and then parent Deutsche Bank) where he advised clients on their corporate and licensing strategies as well as performing due diligence projects for corporates and investors.

David joined Aberdeen Asset Management’s private equity division (spun-out to form Maven in 2009) in September 2007 as Fund Manager for an early-stage technology fund. David has a First-Class Honours degree, a PhD (Molecular Biology/Gene Delivery) from the University of Bath and an MBA from The University of Edinburgh.